Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NAB 741

Next Previous
Drug Profile

NAB 741

Alternative Names: NAB-741; SPR 741

Latest Information Update: 17 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Northern Antibiotics
  • Developer Evotec SE; Spero Therapeutics
  • Class Antibacterials; Peptides; Polymixins
  • Mechanism of Action Cell membrane structure modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gram-negative infections

Most Recent Events

  • 04 Jun 2025 NAB 741 licensed to Prokaryotics worldwide
  • 02 Jun 2025 Prokaryotics receives SBIR grant from National Institute of Allergy and Infectious Diseases for medinamycin analogues development in Acinetobacter infections
  • 02 Jun 2025 Spero Therapeutics plans a phase II trial for Acinetobacter infections (Combination therapy)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top